Stockreport

Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High [Seeking Alpha]

Reviva Pharmaceuticals Holdings, Inc.  (RVPH) 
PDF The company now seeks FDA approval based on existing data, targeting a Q2 2026 NDA, though a second Phase 3 trial may still be required. Three recent dilutive financi [Read more]